Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE

OBJECTIVE: Anifrolumab is a fully human immunoglobulin G(1) κ monoclonal antibody specific for subunit 1 of the type I interferon (IFN) α receptor. In a phase IIb study of adults with moderate to severe SLE, anifrolumab treatment demonstrated substantial reductions in multiple clinical endpoints. He...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Lupus Sci Med
Autores principales: Casey, Kerry A, Guo, Xiang, Smith, Michael A, Wang, Shiliang, Sinibaldi, Dominic, Sanjuan, Miguel A, Wang, Liangwei, Illei, Gabor G, White, Wendy I
Formato: Artigo
Lenguaje:Inglês
Publicado: BMJ Publishing Group 2018
Materias:
Biomarker Studies
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6257383/
https://ncbi.nlm.nih.gov/pubmed/30538817
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/lupus-2018-000286
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares